Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity

被引：0
|
作者：
Jiawei Yue
Hui Guo
Peng Xu
Jinhong Ma
Weifeng Shi
Yumin Wu
机构：
[1] The Third Affiliated Hospital of Soochow University,Department of Orthopaedics
[2] The Third Affiliated Hospital of Soochow University,Department of Laboratory Medicine
[3] Institute of Nano and Soft Materials (FUNSOM) College of Nano Science &Technology (CNST) Suzhou,Jiangsu Key Laboratory for Carbon
来源：
Cancer Immunology, Immunotherapy | / 73卷
关键词：
Group 2 innate lymphoid cells; Interleukin-33; Cancer immunotherapy; Mature ILC2; Programmed cell death protein-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma
    Francesco Noto
    Jacopo Mancini
    Adriana Rosa Gambardella
    Christina Curcio
    Adele De Ninno
    Sara Andreone
    Carla Buccione
    Maria Teresa D’Urso
    Daniele Macchia
    Anna Maria Pacca
    Massimo Spada
    Luca Businaro
    Claudia Afferni
    Fabrizio Mattei
    Giovanna Schiavoni
    Journal of Experimental & Clinical Cancer Research, 44 (1)
  • [22] PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
    Zahm, Christopher D.
    Moseman, Jena E.
    Delmastro, Lauren E.
    G. Mcneel, Douglas
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [23] The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
    Zhao, Zihan
    Liu, Siyang
    Sun, Rui
    Zhu, Wenjie
    Zhang, Yulin
    Liu, Tianyao
    Li, Tianhang
    Jiang, Ning
    Guo, Hongqian
    Yang, Rong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [24] Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy
    Jiang, Mengshi
    Li, Wei
    Zhu, Chunqi
    Li, Xiang
    Zhang, Junlei
    Luo, Zhenyu
    Qin, Bing
    Du, Yongzhong
    Luo, Lihua
    You, Jian
    Journal of Controlled Release, 2021, 329 : 1023 - 1036
  • [25] Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy
    Jiang, Mengshi
    Li, Wei
    Zhu, Chunqi
    Li, Xiang
    Zhang, Junlei
    Luo, Zhenyu
    Qin, Bing
    Du, Yongzhong
    Luo, Lihua
    You, Jian
    JOURNAL OF CONTROLLED RELEASE, 2021, 329 : 1023 - 1036
  • [26] MicroRNA-29a synergizes with PD-1 therapy to regulate anti-tumor immunity
    Leng, Xuebing
    Ristin, Svetlana
    Rafie, Christine
    Buchness, Lance
    Villarino, Alejandro
    Stelekati, Erietta
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV
    Zhang, C.
    Wu, S.
    Xue, X.
    Li, M.
    Qin, X.
    Li, W.
    Han, W.
    Zhang, Y.
    CYTOTHERAPY, 2008, 10 (07) : 711 - 719
  • [28] Targeting metabolic vulnerabilities of MDSCs to enhance the anti-tumor activity of PD-1 blockade in melanoma
    Zheng, B.
    Kim, S.
    Li, M.
    Trousil, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S137 - S137
  • [29] Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade
    Jin, Chengyan
    Zhang, Yan
    Li, Baofeng
    Gao, Tianci
    Wang, Bin
    Hua, Peiyan
    MATERIALS TODAY BIO, 2024, 27
  • [30] AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity
    Ye, Fan
    Huang, Jianing
    Cheng, Xiaoli
    Chen, Shih Chieh
    Huang, Fang
    Huang, Wen-Chin
    Hua, Botong
    Li, Ella
    Jiang, Jenny
    Lin, Hanna
    Siegel, Matthew
    Liao, Eric
    Wang, Ji
    Yue, Bella
    Shi, Wenli
    Xu, Yanghua
    Wang, Xin
    Wang, Jiaming
    Yan, Yuyuan
    He, Honglin
    Liu, Eugene
    Lu, Binfeng
    Zhong, Ziyang
    FRONTIERS IN IMMUNOLOGY, 2025, 16
12345